LXRX Latest Press Releases

-- October 29, 2026 --

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 Globe Newswire 8:30 AM

-- October 23, 2026 --

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy Globe Newswire 8:30 AM

-- October 21, 2026 --

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease Globe Newswire 8:30 AM

-- September 1, 2026 --

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences Globe Newswire 4:05 PM

-- August 31, 2026 --

Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure Globe Newswire 8:30 AM

-- August 24, 2026 --

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 Globe Newswire 8:30 AM

-- August 6, 2026 --

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates Globe Newswire 7:30 AM

-- July 30, 2026 --

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 Globe Newswire 8:30 AM

-- July 27, 2026 --

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) Globe Newswire 8:30 AM

-- June 3, 2026 --

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes